In Vitro Susceptibility of Burkholderia pseudomallei Isolates to Cefiderocol and Ceftazidime/Avibactam from Odisha, India

Abstract

Introduction and Objectives The availability of a limited arsenal of antibacterial agents effective against Burkholderia pseudomallei, the causative agent of melioidosis, together with sporadic reports of emergence of resistance necessitates an evaluation of in vitro activity of new antimicrobials against clinical B. pseudomallei isolates. Cefiderocol (CFDC), a novel siderophore cephalosporin, and ceftazidime-avibactam (CZA), a new β lactam combination agent, have shown promising results for the treatment of difficult-to-treat Gram-negative bacilli infections with limited treatment options. This study was conducted to determine the in vitro activity of CFDC and CZA against a contemporary collection of 60 B. pseudomallei clinical isolates.

Materials and Methods Minimum inhibitory concentrations (MIC) of CFDC and CZA were determined by broth microdilution and E-test, respectively. The performance of disk diffusion was also evaluated for CFDC.

Results All B. pseudomallei isolates were susceptible to CFDC and CZA with MIC range of 0.125 to 2 mg/L and 0.19 to 1 mg/L, respectively. Zone diameters for CFDC ranged from 31 to 40 mm.

Conclusion CFDC and CZA exhibited excellent in vitro activity against 60 B. pseudomallei isolates. Further pharmacokinetic-pharmacodynamics studies and clinical trials are needed to prove the clinical efficacy of CFDC and CZA in the treatment of melioidosis.

Keywords

Burkholderia pseudomallei - Cefiderocol - Ceftazidime-avibactam

Publikationsverlauf

Eingereicht: 20. Januar 2023

Angenommen: 19. April 2023

Artikel online veröffentlicht:
13. Juni 2023

• References

• 1 Sullivan RP, Marshall CS, Anstey NM, Ward L, Currie BJ. 2020 Review and revision of the 2015 Darwin melioidosis treatment guideline; paradigm drift not shift. PLoS Negl Trop Dis 2020; 14 (09) e0008659
• 2 Schweizer HP. Mechanisms of antibiotic resistance in Burkholderia pseudomallei: implications for treatment of melioidosis. Future Microbiol 2012; 7 (12) 1389-1399
• 3 Sarovich DS, Price EP, Von Schulze AT. et al. Characterization of ceftazidime resistance mechanisms in clinical isolates of Burkholderia pseudomallei from Australia. PLoS One 2012; 7 (02) e30789
• 4 Chantratita N, Rholl DA, Sim B. et al. Antimicrobial resistance to ceftazidime involving loss of penicillin-binding protein 3 in Burkholderia pseudomallei. Proc Natl Acad Sci U S A 2011; 108 (41) 17165-17170
• 5 Sarovich DS, Price EP, Limmathurotsakul D. et al. Development of ceftazidime resistance in an acute Burkholderia pseudomallei infection. Infect Drug Resist 2012; 5: 129-132
• 6 Kung CT, Lee CH, Li CJ, Lu HI, Ko SF, Liu JW. Development of ceftazidime resistance in Burkhoderia pseudomallei in a patient experiencing melioidosis with mediastinal lymphadenitis. Ann Acad Med Singap 2010; 39 (12) 945-3
• 7 Behera B, Prasad Babu TL, Kamalesh A, Reddy G. Ceftazidime resistance in Burkholderia pseudomallei: first report from India. Asian Pac J Trop Med 2012; 5 (04) 329-330
• 8 Sarovich DS, Webb JR, Pitman MC. et al. Raising the Stakes: loss of efflux pump regulation decreases meropenem susceptibility in Burkholderia pseudomallei. Clin Infect Dis 2018; 67 (02) 243-250
• 9 Parsels KA, Mastro KA, Steele JM, Thomas SJ, Kufel WD. Cefiderocol: a novel siderophore cephalosporin for multidrug-resistant gram-negative bacterial infections. J Antimicrob Chemother 2021; 76 (06) 1379-1391
• 10 Shirley M. Ceftazidime-avibactam: a review in the treatment of serious gram-negative bacterial infections. Drugs 2018; 78 (06) 675-692
• 11 Tellapragada C, Shaw T, D'Souza A, Eshwara VK, Mukhopadhyay C. Improved detection of Burkholderia pseudomallei from non-blood clinical specimens using enrichment culture and PCR: narrowing diagnostic gap in resource-constrained settings. Trop Med Int Health 2017; 22 (07) 866-870
• 12 Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing; Twenty Ninth Informational Supplement. M100-S29. Wayne, PA: Clinical and Laboratory Standards Institute; 2019
• 13 Clinical and Laboratory Standards Institute. 2020. Performance Standards for Antimicrobial Susceptibility Testing; Thirtieth Informational Supplement. M100-S30. Wayne, PA: Clinical and Laboratory Standards Institute; 2020
• 14 Burnard D, Robertson G, Henderson A. et al. Burkholderia pseudomallei clinical isolates are highly susceptible in vitro to cefiderocol, a siderophore cephalosporin. Antimicrob Agents Chemother 2021; 65 (02) e00685-e20
• 15 Tsuji M, Jakielaszek C, Marchand CL. S-649266, a novel siderophore cephalosporin: in vitro activity against biothreat pathogen. Open Forum Infect Dis 2016; 3 (Suppl 1): 1832
• 16 Morris CP, Bergman Y, Tekle T, Fissel JA, Tamma PD, Simner PJ. Cefiderocol antimicrobial susceptibility testing against multidrug-resistant gram-negative Bacilli: a comparison of disk diffusion to broth microdilution. J Clin Microbiol 2020; 59 (01) e01649-e20
• 17 Bonnin RA, Emeraud C, Jousset AB, Naas T, Dortet L. Comparison of disk diffusion, MIC test strip and broth microdilution methods for cefiderocol susceptibility testing on carbapenem-resistant enterobacterales. Clin Microbiol Infect 2022; 28 (08) 1156.e1-1156.e5
• 18 Matuschek E, Longshaw C, Takemura M, Yamano Y, Kahlmeter G. Cefiderocol: EUCAST criteria for disc diffusion and broth microdilution for antimicrobial susceptibility testing. J Antimicrob Chemother 2022; 77 (06) 1662-1669
• 19 Sribenjalux W, Wonglakorn L, Meesing A. In vitro susceptibility of Burkholderia pseudomallei isolates from Thai patients to ceftolozane/tazobactam and ceftazidime/avibactam. J Glob Antimicrob Resist 2022; 28: 8-11
• 20 Chirakul S, Somprasong N, Norris MH. et al. Burkholderia pseudomallei acquired ceftazidime resistance due to gene duplication and amplification. Int J Antimicrob Agents 2019; 53 (05) 582-588